A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)

NCT04679103 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

BIOLOGICAL: Eculizumab (JSC GENERIUM, Russia)

Sponsor

AO GENERIUM